What is Ginkgo Bioworks's marketable securities?

Ginkgo Bioworks (DNA) reported marketable securities of $229.59M in Q1 2026.

How has Ginkgo Bioworks's marketable securities changed year-over-year?

Ginkgo Bioworks's marketable securities increased by 12.3% year-over-year, from $204.5M to $229.59M.

Ginkgo Bioworks DNA Marketable Securities

Marketable Securities at other companies

General DynamicsGD

$207M-1.0%

KLA CorporationKLAC

$3.17B+46.1%

Dime Community Bancshares DCOM

$63.66M-5.0%

DexComDXCM

$1.3B—

CitigroupC

$6.29B+9.7%

Burke & Herbert Financial Services Corp.BHRB

$45.81M+30.5%

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecurities.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's marketable securities?: Ginkgo Bioworks (DNA) reported marketable securities of $229.59M in Q1 2026.
How has Ginkgo Bioworks's marketable securities changed year-over-year?: Ginkgo Bioworks's marketable securities increased by 12.3% year-over-year, from $204.5M to $229.59M.